Overview

  • Product nameAnti-AP2 alpha antibody [AP2a 8G8/5]
    See all AP2 alpha primary antibodies
  • Description
    Mouse monoclonal [AP2a 8G8/5] to AP2 alpha
  • SpecificityDoes not cross-react with AP2 beta or Ap2 gamma.
  • Tested applicationsSuitable for: WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Bacterial AP2 alpha/AP2 gamma fusion protein.

  • Positive control
    • Raji cells or breast carcinoma

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Concentration information loading...
  • PurityIgG fraction
  • ClonalityMonoclonal
  • Clone numberAP2a 8G8/5
  • IsotypeIgG1
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab18112 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Predicted molecular weight: 50 kDa.
IHC-P Use at an assay dependent concentration.

Target

  • FunctionSequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. AP-2-alpha is the only AP-2 protein required for early morphogenesis of the lens vesicle.
  • Involvement in diseaseDefects in TFAP2A are the cause of branchiooculofacial syndrome (BOFS) [MIM:113620]; also known as branchial clefts with characteristic facies, growth retardation, imperforate nasolacrimal duct, and premature aging or lip pseudocleft-hemangiomatous branchial cyst syndrome. BOFS is a rare autosomal dominant cleft palate craniofacial disorder with variable expressivity. The major features include cutaneous anomalies, ocular anomalies, characteristic facial appearance (malformed pinnae, oral clefts), and, less commonly, renal and ectodermal (dental and hair) anomalies.
  • Sequence similaritiesBelongs to the AP-2 family.
  • DomainThe WW-binding motif mediates interaction with WWOX.
  • Post-translational
    modifications
    Sumoylated on Lys-10; which inhibits transcriptional activity.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • Activating enhancer binding protein 2 alpha antibody
    • Activating enhancer-binding protein 2-alpha antibody
    • Activator protein 2 antibody
    • AP 2 transcription factor antibody
    • AP 2alpha antibody
    • AP-2 antibody
    • AP-2 transcription factor antibody
    • AP2 antibody
    • AP2 Transcription Factor antibody
    • AP2-alpha antibody
    • AP2A_HUMAN antibody
    • AP2TF antibody
    • BOFS antibody
    • FLJ51761 antibody
    • TFAP 2 antibody
    • TFAP 2A antibody
    • TFAP2 antibody
    • TFAP2A antibody
    • Transcription factor AP 2 alpha (activating enhancer binding protein 2 alpha) antibody
    • Transcription factor AP-2-alpha antibody
    • Transcription factor AP2 alpha antibody
    see all

Anti-AP2 alpha antibody [AP2a 8G8/5] images

  • Immunohistochemical analysis of bladder cancer tissue, staining AP2 alpha with ab18112 at 1/40 dilution.

References for Anti-AP2 alpha antibody [AP2a 8G8/5] (ab18112)

This product has been referenced in:
  • Nordentoft I  et al. Increased expression of transcription factor TFAP2a correlates with chemosensitivity in advanced bladder cancer. BMC Cancer 11:135 (2011). WB, IHC-P ; Human . Read more (PubMed: 21489314) »
  • Bennett KL  et al. AP-2alpha induces epigenetic silencing of tumor suppressive genes and microsatellite instability in head and neck squamous cell carcinoma. PLoS One 4:e6931 (2009). WB ; Human . Read more (PubMed: 19742317) »

See all 2 Publications for this product

Product Wall

Thank you for your enquiry. Raji cells or breast carcinoma can be used as a positive control for this antibody. I hope this information helps, please do not hesitate to contact us if you need any more advice or information.

Thank you for your enquiry. I received the following information from the source of this antibody - we "don't know the precise epitope recognized by 8G8, but due to the antigen used to raise this antibody, it must lie within the sequence: aa165 GINIPDQ...

Read More

Thank you for your enquiry. All the information we have on species cross reactivity is specified on the datasheet, these are updated as soon as any new information is brought to our attention. As far as we are aware, cross reactivity with mouse h...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"